Fujifilm Corp., aiming to accelerate the overseas expansion of its possible COVID-19 drug Avigan, is partnering with a major Indian drug manufacturer and a major pharmaceutical distributor in the United Arab Emirates, the company announced Wednesday.
By allowing the overseas manufacture and sale of Avigan, Fujifilm is building a system that can meet an increase in demand for the medicine.
Avigan developer Fujifilm Toyama Chemical Co., a subsidiary of Fujifilm, has granted licenses to the two companies for the manufacture and sale of the drug in return for contractual fees and royalties. The overseas companies can sell their products exclusively overseas, except in China and Russia.
The two overseas companies will conduct clinical trials in India and Kuwait based on data from tests provided by Fujifilm. Sales will begin once the companies gain approval from the relevant authorities.
Avigan was created as a drug to treat new strains of influenza. Clinical trials of Avigan are underway in Japan and the United States for patients infected with the novel coronavirus.
Read more from The Japan News at https://japannews.yomiuri.co.jp/
